Eli Lilly secures full FDA approval for Retevmo, expanding use of its RET inhibitor

Eli Lilly said the U.S. Food and Drug Administration has granted full approval for Retevmo, its targeted cancer medicine selpercatinib, broadening the patient population eligible to receive the drug. The change matters because “full approval” reflects the FDA’s determination based on more mature evidence, rather than the earlier pathway used for “accelerated approval,” which can be granted while confirmatory data are still being developed.

Retevmo is a RET inhibitor, meaning it is designed to interfere with indicating driven by abnormal RET changes found in some tumors. The reported label expansion covers adults and pediatric patients with RET fusion solid tumors, according to the Yahoo Finance report dated July 15, 2026.

The report says the FDA’s action shifts selpercatinib from accelerated approval to traditional approval. In practical terms for patients and clinicians, it typically indicates that the FDA has received sufficient evidence to validate clinical benefit under the standard approval framework, rather than relying on earlier surrogate endpoints used under the accelerated program.

Because the Yahoo Finance post summarized the decision at a high level, specific details on the expanded indication scope were not included in the material available for this review. For example, the report did not outline the exact cancer types, biomarker testing requirements, or line-of-therapy limitations that may appear in the final prescribing information and FDA label.

Eli Lilly’s oncology strategy has leaned heavily on precision medicine, including treatments that target specific genetic drivers. In that context, broader approval for a biomarker-defined drug can expand the addressable market, support physician adoption, and potentially reduce payer and formulary friction that sometimes follows accelerated approvals and confirmatory studies.

The broader use across both adults and pediatrics also underscores the FDA’s willingness to treat children and adolescents under molecularly defined tumor criteria, if the evidence package supports it. Pediatric indications are often subject to careful review given the smaller patient populations and different clinical trial feasibility, so label expansions can be significant for pediatric oncology practices.

What is not clear from the available post is whether the full approval affects dosing, safety monitoring, or whether any new restrictions apply compared with the accelerated approval label. The report also did not specify whether Lilly simultaneously updated the drug’s label language for particular tumor histologies, prior treatment statuses, or geographic or regulatory differences across agencies.

Going forward, investors and clinicians will likely focus on updates from Lilly regarding the timing of label changes in the U.S., any confirmatory study results referenced in the FDA’s review, and whether payers adjust coverage decisions following the switch to traditional approval. Additional guidance from the FDA, including the final label and any accompanying review documents, will determine how broadly the expanded indication can be applied in real-world settings.